Where is Zandcell located?

Zandcell is headquartered in Las Vegas, United States.

Is Zandcell a funded company?

Zandcell is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Zandcell rank among its competitors?

Zandcell ranks 3152nd amongst 2440 active competitors, of which 634 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Zandcell?

Zandcell's top competitors include Sana Biotechnology, Spark Therapeutics and Synthego. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Zandcell - 2026 Company Profile & Competitors

Company Details

Website: zandcelltech.com
Email ID: *****@zandcelltech.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Las Vegas, United States

Stage

Deadpooled

Ranked

3152^nd among 3277 competitors

Similar Companies

Sana Biotechnology & 3275 more

View Zandcell's full profile

Zandcell has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zandcell include Sana Biotechnology, Spark Therapeutics and Synthego. Here is the list of Top 10 competitors of Zandcell, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	74/100
3rd	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
4th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
5th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	70/100
6th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
7th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
8th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
9th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 9 others	69/100
10th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
3152nd	Zandcell 2018, Las Vegas (United States), Deadpooled	Developer of molecular techniques in genomics, proteomics, and medicine	-	-	15/100